Alterity Therapeutics Ltd (ATHE) stock
Close on Nov 16, 2026Market cap $35.53MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- A$51.67M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -43.59%
Fundamentals
- Free cash flow
- -A$22.52M
Trading
- Previous close
- $1.96
- Open
- $1.96
- Day's range
- $1.89 – $2.05
- Volume
- 13,410
- Average volume (20 days)
- 233,537
- Beta (5 years)
- 0.95
- RSI (14 days)
- 31.9
- Volatility (1 year)
- 69.2%
- Relative volume
- 0.20×
- WACC
- 9.9%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | ATHE | S&P 500 | Difference | ATHE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.2% | -3.1% | −22.1 pts | ||
| 3 months | -59.1% | -4.5% | −54.6 pts | ||
| Year to date | -36.4% | +9.4% | −45.7 pts | ||
| 1 year | -49.0% | +11.3% | −60.3 pts | ||
| 3 years | -16.6% | +70.4% | −87.0 pts | -5.9% | +19.4% |
| 5 years | -82.7% | +68.6% | −151.2 pts | -29.6% | +11.0% |
| 10 years | -93.3% | +297.7% | −391.0 pts | -23.7% | +14.8% |
Twelve years at a glance
Fiscal years 2015 to 2026, AUD
Revenue
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alterity Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Alterity Therapeutics
Pharmaceutical Preparations
Alterity Therapeutics Limited is a clinical-stage biotechnology company focused on creating treatments for neurodegenerative conditions. The company utilizes a proprietary chemical library and platform technology aimed at redistributing excess labile iron and addressing protein aggregation in the central nervous system. Its lead oral drug candidate, ATH434, is designed to reduce alpha-synuclein pathology and preserve neurons, with primary clinical development focused on Multiple System Atrophy, alongside research in Parkinson’s disease and other disorders.
Company profile, executives and historyAlterity Therapeutics stock: common questions
What is Alterity Therapeutics's stock price?
ATHE closed at $1.96 on Nov 16, 2026, up 0.00% on the day.
What is Alterity Therapeutics's market cap?
Alterity Therapeutics was worth $35.53M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
Does Alterity Therapeutics pay a dividend?
No. Alterity Therapeutics has not paid a cash dividend over the last twelve months.
How has ATHE stock performed over the past year?
Including dividends, ATHE returned -49.0% over the past year, against +11.3% for the S&P 500.
Who are Alterity Therapeutics's competitors?
Companies most similar to Alterity Therapeutics by business, industry and size include GANX, CRVO, CLNN, ANVS, SER.
See a number that looks wrong?